首页 | 本学科首页   官方微博 | 高级检索  
     

参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌的临床效果观察
引用本文:陈红宙. 参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌的临床效果观察[J]. 现代保健, 2013, 0(23): 37-38
作者姓名:陈红宙
作者单位:浙江省奉化市中医院,浙江奉化315500
摘    要:目的:探讨参赭培气汤联合FOLFOX4化疗治疗晚期肝癌的临床疗效及安全性。方法:选择本院近年来收治的晚期肝癌患者78例为研究对象,随机分为参赭培气汤组38例和对照组40例,对照组给予放化疗治疗,参赭培气汤组在放化疗基础上加用参赭培气汤治疗,对比分析两组患者的近期疗效及毒副反应发生情况。结果:参赭培气汤组化疗的近期总有效率显著高于对照组(P〈0.05),且治疗期间毒副反应发生率明显低于对照组(P〈0.05)。结论:参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌临床疗效满意,毒副反应少,安全、有效,值得临床推广应用。

关 键 词:参赭培气汤  肝癌  临床疗效  毒副反应

Clinical Efficacy of Canzhepeiqi Soup Combined with FOLFOX4 Chemotherapy Regimens in Treatment of Advanced Liver Cancer
CHEN Hong-zhou. Clinical Efficacy of Canzhepeiqi Soup Combined with FOLFOX4 Chemotherapy Regimens in Treatment of Advanced Liver Cancer[J]. , 2013, 0(23): 37-38
Authors:CHEN Hong-zhou
Affiliation:CHEN Hong-zhou Fenghua TCM Hospital of Zhejiang Province, Fenghua 315500,. China
Abstract:Objective: To explore the clinical efficacy and safety of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer.Method: To choose the advanced liver cancer patients in our hospital as the research object in recent years, and divided into Canzhepeiqi Soup group and control group randomly, to contrast and analyze the recent curative effect and adverse reaction.Result: The total effective rate of Canzhepeiqi Soup group was significantly higher than control group in the near future ( P〈0.05 ), and the incidence rate of adverse reaction was significantly lower than control group ( P〈0.05 ) .Conclusion: Clinical efficacy of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer is satisfied, and has less adverse reaction, it is safe and effective, is worthy of popularization and applicationl
Keywords:Ctinzhepeiqi Soup  Liver cancer  Clinical efficacy  Adverse reaction
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号